Everolimus

Evidence-based neurology checklist on everolimus: Mode of action Everolimus is an mTOR inhibitor (mechanistic target of rapamycin) Indications Dosing Infectious side effects Systemic side effects

Mode of action

  • Everolimus is an mTOR inhibitor (mechanistic target of rapamycin)

Indications

Dosing

Infectious side effects

Systemic side effects

References

  1. Curatolo P. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy. Pediatr Neurol 2015; 52:281-289.
  2. Krueger DA, Wilfong AA, Mays M, et al. Long-term treatment of epilepsy with everolimus in tuberous sclerosis. Neurology 2016; 87:2408-2415.
  3. Krueger DA, Wilfong AA, Holland-Bouley K, et al. Everolimus treatment of refractory epilepsy in tuberous sclerosis complex. Ann Neurol 2013; 74:679-687. 
  4. Samueli S, Abraham K, Dressler A, et al. Efficacy and safety of Everolimus in children with TSC-associated epilepsy-pilot data from an open single-center prospective study. Orphanet J Rare Dis 2016; 11:145.
  5. Wiegand G, May TW, Ostertag P, Boor R, Stephani U, Franz DN. Everolimus in tuberous sclerosis patients with intractable epilepsy: a treatment option? Eur J Paediatr Neurol 2013; 17:631-638.

Related checklists

Loading...